Why is "Afatinib" trending?

Search Interest Perspective

• Neoadjuvant tislelizumab with afatinib for locally advanced head and neck squamous cell carcinoma (neoCHANCE-1): a phase 2 clinical trial - Nature
• Recurrent Nasopharyngeal Chordoma Stabilized With Afatinib: A Case Report - Cureus
• Surgical Resection With EGFR TKI Demonstrates Promising PFS in EGFR -Mutant NSCLC - The ASCO Post
• Two Cases of Epidermal Growth Factor Receptor L861R Mutation-Positive Lung Adenocarcinoma Treated With Osimertinib and Afatinib - Wiley Online Library
• Personalizing Treatment for Atypical EGFR-Mutated NSCLC - OncLive
• Efficacy and safety findings of the EXTRA study in older adult EGFR-mutant lung cancer patients receiving afatinib as first-line treatment | Scientific Reports - Nature
• Afatinib Improved PFS in Lung Cancer With Uncommon Mutations - MedPage Today
• Real-World Analysis: Osimertinib Shows Superior Survival for Patients With Atypical EGFR-Mutated mNSCLC - Docwire News
• Novel drug combination overcomes resistance in aggressive KRAS-mutated lung cancer - News-Medical
• Osimertinib vs Afatinib for NSCLC After EGFR-TKI Treatment Failure - Pulmonology Advisor
• Afatinib amplifies cAMP-induced fluid secretion in a mouse mini-gut model via TMEM16A-mediated fluid secretion and secretory cell differentiation - Nature
• Navigating Post-Afatinib Progression: Treatment Sequencing Strategies in NSCLC - OncLive
• Case report: First report of metastatic esophageal squamous cell carcinoma with EGFR p.S768I mutation: remarkable response to third-generation EGFR -TKI - Nature
• Neoadjuvant Afatinib for stage III EGFR -mutant non-small cell lung cancer: a phase II study - Nature
• The inhibitory effect and targets of CRM197 on tumor growth in arsenic-transformed cells and lung cancer cells - Nature
• Long term efficacy of first-line afatinib and the clinical utility of ctDNA monitoring in patients with suspected or confirmed EGFR mutant non-small cell lung cancer who were unsuitable for chemotherapy - Nature
• Population pharmacokinetics of afatinib and exposure-safety relationships in Japanese patients with EGFR mutation-positive non-small cell lung cancer - Nature
• Randomized phase II study of preoperative afatinib in untreated head and neck cancers: predictive and pharmacodynamic biomarkers of activity - Nature
• An alternative EGFR activation by patient-derived R252C mutation promotes cancer progression - Nature
• Phase II trial of afatinib in patients with advanced urothelial carcinoma with genetic alterations in ERBB1-3 (LUX-Bladder 1) | British Journal of Cancer - Nature
• Activity of afatinib in patients with NSCLC harboring novel uncommon EGFR mutations with or without co-mutations: a case report - Frontiers
• Afatinib Outperforms First-Generation EGFR-TKIs in NSCLC With Uncommon EGFR Mutations - AJMC
• Clinical efficacy and identification of factors confer resistance to afatinib (tyrosine kinase inhibitor) in EGFR-overexpressing esophageal squamous cell carcinoma - Nature
• Case Report: Afatinib-Induced Interstitial Pneumonia: Experiences and Lessons From Two Patients - Frontiers
• Case Report: Afatinib Treatment in a Patient With NSCLC Harboring a Rare EGFR Exon 20 Mutation - Frontiers
• Anti-inflammatory effect of afatinib (an EGFR-TKI) on OGD-induced neuroinflammation - Nature
• Afatinib plus PEM and CBDCA overcome osimertinib resistance in EGFR -mutated NSCLC with high thrombospondin-1 expression - Wiley Online Library
• Optimizing Afatinib Use: Dosing Strategies and Adverse Event Management - OncLive
• Afatinib-Associated Cutaneous Toxicity: A Correlation of Severe Skin Reaction with Dramatic Tumor Response in a Woman with Exon 19 Deletion Positive Non-Small-Cell Lung Cancer - Cureus
• Late-Stage Afatinib Trials Halted in Head and Neck Cancer - OncLive
• Takotsubo cardiomyopathy Afatinib-related in a non-small cell lung cancer patient: Case report - Frontiers
• Targeting Rare EGFR Mutations in NSCLC: Afatinib and Mobocertinib - CancerNetwork
• Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials - The Lancet
• Afatinib Tablets Now Available for Use in Treatment of NSCLC - OncLive
• Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial - The Lancet
• Ankyrin Repeat Domain 1 Overexpression is Associated with Common Resistance to Afatinib and Osimertinib in EGFR-mutant Lung Cancer - Nature
• Plain language summary: the potential role of afatinib in treating people with NRG1 gene fusion-positive cancer - Oncology Central
• Mechanism of Action: Afatinib (BIBW 2992) - Targeted Oncology
• Effective Treatment With Afatinib of Lung Adenocarcinoma With Leptomeningeal Metastasis Harboring the Exon 18 p.G719A Mutation in the EGFR Gene Was Detected in Cerebrospinal Fluid: A Case Report - Frontiers
• Dr Mekhail on Afatinib in Lung Cancers With Uncommon EGFR Mutations - OncLive
• Afatinib Approval for Lung Cancer Expanded by FDA - Targeted Oncology
• Blocking autophagy improves the anti-tumor activity of afatinib in lung adenocarcinoma with activating EGFR mutations in vitro and in vivo - Nature
• Targeted Therapies for NSCLC With Nonclassical EGFR Mutations Grow Increasingly Personalized - OncLive
• Identification of afatinib-associated ADH1B and potential small-molecule drugs targeting ADH1B for hepatocellular carcinoma - Frontiers
• Afatinib shows increased progression-free survival in non-small-cell lung cancer - 2 Minute Medicine
• Case Report: Afatinib Sensitivity in Rare EGFR E746_L747delinsIP Mutated LUAD With Peritoneal Metastases - Frontiers
• Impact of Dose Reduction of Afatinib Used in Patients With Non–Small Cell Lung Cancer: A Systematic Review and Meta-Analysis - Frontiers
• Afatinib in NSCLC with uncommon EGFR mutations - Oncology Central
• GPCR-mediated EGFR transactivation ameliorates skin toxicities induced by afatinib - Nature
• FDA approves Gilotrif® (afatinib) as new oral treatment option for patients with squamous cell carcinoma of the lung - PR Newswire
• FDA Approves Afatinib for Advanced Lung Cancer - CancerNetwork
• FDA Expands Use of Lung Cancer Therapeutic - American Association for Cancer Research (AACR)
• Toxic epidermal necrosis associated with afatinib: A case report and literature review - Frontiers
• Case report: Aumolertinib plus gumarontinib in a patient with EGFR mutated non-small-cell lung cancer harboring acquired MET amplification following progression on afatinib plus crizotinib - Frontiers
• Sequential treatment of afatinib and osimertinib or other regimens in patients with advanced non-small-cell lung cancer harboring EGFR mutations: Results from a real-world study in South Korea - Wiley Online Library
• Phase 1 trial of dasatinib combined with afatinib for epidermal growth factor receptor- (EGFR-) mutated lung cancer with acquired tyrosine kinase inhibitor (TKI) resistance - Nature
• Lung Adenocarcinoma Patient Harboring EGFR-KDD Achieve Durable Response to Afatinib: A Case Report and Literature Review - Frontiers
• Afatinib Market| Size & Trend Projection 2026- 2035 - Business Research Insights
• OTT - Dove Medical Press
• Case Report: A patient with the rare third-generation TKI-resistant mutation EGFR L718Q who responded to afatinib plus cetuximab combination therapy - Frontiers
• Case Study: Significant Tumor Response in Non-Small Cell Lung Cancer with - Bioengineer.org
• Afatinib for the first-line treatment of EGFR mutation-positive NSCLC in China: a review of clinical data - Oncology Central
• Afatinib combined with anti-PD1 enhances immunotherapy of hepatocellular carcinoma via ERBB2/STAT3/PD-L1 signaling - Frontiers
• The ratio of T790M to EGFR-activating mutation predicts response of osimertinib in 1st or 2nd generation EGFR-TKI-refractory NSCLC - Nature
• Sequential afatinib and osimertinib in patients with EGFR mutation-positive NSCLC: updated analysis of the observational GioTag study - Oncology Central
• Efficacy of afatinib, an irreversible ErbB family blocker, in the treatment of intracerebral metastases of non-small cell lung cancer in mice - Nature
• Gilotrif (afatinib) for the Treatment of Metastatic Non-Small cell Lung Cancer - Clinical Trials Arena
• One-Two Punch: Novel Drug Pairing Could Beat Pancreatic Cancer - UC San Diego Health
• Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR -mutant NSCLC - Nature
• Researchers find 'highly synergistic' combo featuring Mirati's Krazati in pancreatic cancer models - Fierce Biotech
• Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells - Nature
• Afatinib (Gilotrif) - Oncology Nurse Advisor
• Preclinical assessment of combination therapy of EGFR tyrosine kinase inhibitors in a highly heterogeneous tumor model - Nature
• GILOTRIF (afatinib) for Non-small Cell Lung Cancer - Cancer Therapy Advisor
• Afatinib for patients with EGFR mutation positive lung cancer - Hospital Pharmacy Europe
• Successful sequential tyrosine kinase inhibitors to overcome a rare compound of EGFR exon 18–18 and EGFR amplification: A case report - Frontiers
• Survey of ex vivo drug combination effects in chronic lymphocytic leukemia reveals synergistic drug effects and genetic dependencies - Nature
• Afatinib-induced Interstitial Lung Disease Successfully Treated with Corticosteroids: Case Report and Review of the Literature - Cureus
• Scientists can now see where the drug is going in the body, cell by cell - India Today
• EGFR-TKIs - induced cardiotoxicity in NSCLC: incidence, evaluation, and monitoring - Frontiers
• NSCLC patients with rare EGFR Ex19del/G724S mutation showed good response to afatinib combined with chemotherapy treatment: A two-case report - Frontiers
• Development of two different formats of heterogeneous fluorescence immunoassay for bioanalysis of afatinib by employing fluorescence plate reader and KinExA 3200 immunosensor - Nature
• Investigations of Targeted Therapies for NRG1 Fusion–Positive Cancers - Targeted Oncology
• First-line treatment for advanced or metastatic EGFR mutation-positive non-squamous non-small cell lung cancer: a network meta-analysis - Frontiers
• LUX-Lung 7: Phase 2b trial of afatinib versus gefitinib for EGFR-mutated lung cancer in first-line - European Medical Journal
• Organoids in Lung Cancer Management - Frontiers
• European Journal of Dermatology - jle.com
• The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M - Nature
• Comprehensive mutational scanning of EGFR reveals TKI sensitivities of extracellular domain mutants - Nature
• Advancement of First-Line Treatments on EGFR-Mutated NSCLC - CancerNetwork
• Identification of synergistic drug combinations using breast cancer patient-derived xenografts - Nature
• Topical JAK inhibition ameliorates EGFR inhibitor–induced rash in rodents and humans - Science | AAAS
• HER2 G776S mutation promotes oncogenic potential in colorectal cancer cells when accompanied by loss of APC function - Nature
• FDA Approves QIAGEN's therascreen EGFR Test as Companion Diagnostic for Lung Cancer Patients - Clinical Lab Products
• Managing Resistance to Targeted Agents: The Future of NSCLC Therapy - The ASCO Post
• Boehringer stops Giotrif head and neck trials - PharmaTimes
• Efficacy of Osimertinib in NSCLC Harboring Uncommon EGFR L861Q and Concurrent Mutations: Case Report and Literature Review - Frontiers
• GZ17-6.02 and Pemetrexed Interact to Kill Osimertinib-Resistant NSCLC Cells That Express Mutant ERBB1 Proteins - Frontiers
• Amivantamab/Lazertinib Shows Potential in Atypical EGFR-Mutant Lung Cancer - Targeted Oncology
• Management of Brain Metastases in Epidermal Growth Factor Receptor Mutant Non-Small-Cell Lung Cancer - Frontiers